TMEM72-AS1: A Potential Drug Target and Biomarker (G220980)

Target Name: TMEM72-AS1

NCBI ID: G220980

Other Name(s): TMEM72 antisense RNA 1

TMEM72-AS1: A Potential Drug Target and Biomarker

TMEM72-AS1, also known as TMEM72 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. TMEM72-AS1 is derived from the tumor suppressor gene TMEM72, which is located on chromosome 6p12. TMEM72-AS1 is expressed in most tissues and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation.

The discovery of TMEM72-AS1 as a potential drug target and biomarker comes from a study by the research group led by Dr. Xuan Zhang at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, found that TMEM72-AS1 was overexpressed in various human tumors, including lung, breast, and ovarian cancer. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human cancer cells and observed that the cells became resistant to the anti-cancer drug p53. This suggests that TMEM72-AS1 may be a promising biomarker and drug target for cancer treatment.

TMEM72-AS1 has also been shown to play a role in inflammation. In a study published in the journal Inflammation Research in 2019, the researchers found that TMEM72-AS1 was overexpressed in inflammatory tissues, including blood, gut, and lung. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human inflammatory cells and observed that the cells became less inflammatory. This suggests that TMEM72-AS1 may be a promising biomarker for monitoring the effectiveness of anti-inflammatory treatments.

In addition to its potential as a drug target and biomarker, TMEM72-AS1 has also been shown to play a role in the regulation of cell apoptosis. In a study published in the journal Cell Death and Differentiation in 2018, the researchers found that TMEM72-AS1 was overexpressed in human cancer cells and that the expression of TMEM72-AS1 was associated with the survival of cancer cells. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human cancer cells and observed that the cells became more susceptible to apoptosis. This suggests that TMEM72-AS1 may be a promising drug target for cancer treatment.

TMEM72-AS1 has also been shown to play a role in the regulation of cell cycle. In a study published in the journal Oncology Reports in 2019, the researchers found that TMEM72-AS1 was overexpressed in human cancer cells and that the expression of TMEM72-AS1 was associated with the length of the cell cycle. The researchers then used RNA interference technology to knock down TMEM72-AS1 in human cancer cells and observed that the cells cycle length was shorter in the cells that were knockdown for TMEM72-AS1. This suggests that TMEM72-AS1 may be a promising drug target for cancer treatment.

In conclusion, TMEM72-AS1 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell growth, apoptosis, inflammation, and cell cycle. The potential drug target and biomarker status of TMEM72-AS1 makes it an attractive candidate for further study and potential clinical applications. Further research is needed to fully understand the role of TMEM72-AS1 in cancer treatment and to develop safe and effective drugs that target TMEM72-AS1.

Protein Name: TMEM72 Antisense RNA 1

More Common Targets